Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303685481> ?p ?o ?g. }
- W4303685481 endingPage "2511" @default.
- W4303685481 startingPage "2511" @default.
- W4303685481 abstract "Background: Breast cancer is the most common form of cancer in women worldwide. Advances in the early diagnosis and treatment of cancer in the last decade have progressively decreased the cancer mortality rate, and in recent years, immunotherapy has emerged as a relevant tool against cancer. HER2+ and triple-negative breast cancers (TNBCs) are considered more immunogenic and suitable for this kind of treatment due to the higher rate of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression. In TNBC, genetic aberrations further favor immunogenicity due to more neo-antigens in cancer cells. Methods: This review summarizes the principal ongoing conventional and investigational immunotherapies in breast cancer. Particularly, immune checkpoint inhibitors (ICIs) and their use alone or combined with DNA damage repair inhibitors (DDRis) are described. Then, the issue on immunotherapy with monoclonal antibodies against HER-2 family receptors is updated. Other investigational immunotherapies include a new schedule based on the interferon beta-interleukin-2 sequence that was given in ER+ metastatic breast cancer patients concomitant with anti-estrogen therapy, which surprisingly showed promising results. Results: Based on the scientific literature and our own findings, the current evaluation of tumor immunogenicity and the conventional model of adjuvant chemotherapy (CT) are questioned. Conclusions: A novel strategy based on additional prolonged adjuvant immunotherapy combined with hormone therapy or alternated with CT is proposed." @default.
- W4303685481 created "2022-10-09" @default.
- W4303685481 creator A5023003861 @default.
- W4303685481 creator A5056157710 @default.
- W4303685481 creator A5081012227 @default.
- W4303685481 date "2022-10-08" @default.
- W4303685481 modified "2023-10-01" @default.
- W4303685481 title "Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy" @default.
- W4303685481 cites W1488814076 @default.
- W4303685481 cites W1521496787 @default.
- W4303685481 cites W1531775950 @default.
- W4303685481 cites W1548581509 @default.
- W4303685481 cites W176980035 @default.
- W4303685481 cites W1786051985 @default.
- W4303685481 cites W1895813995 @default.
- W4303685481 cites W1940241680 @default.
- W4303685481 cites W1970689588 @default.
- W4303685481 cites W1975704872 @default.
- W4303685481 cites W2000609012 @default.
- W4303685481 cites W2001868807 @default.
- W4303685481 cites W2002157461 @default.
- W4303685481 cites W2004630197 @default.
- W4303685481 cites W2006986876 @default.
- W4303685481 cites W2009134281 @default.
- W4303685481 cites W2009614326 @default.
- W4303685481 cites W2009995818 @default.
- W4303685481 cites W2019502665 @default.
- W4303685481 cites W2019895529 @default.
- W4303685481 cites W2023915585 @default.
- W4303685481 cites W2034596011 @default.
- W4303685481 cites W2046972425 @default.
- W4303685481 cites W2054851015 @default.
- W4303685481 cites W2060133690 @default.
- W4303685481 cites W2063480251 @default.
- W4303685481 cites W2066420422 @default.
- W4303685481 cites W2084310444 @default.
- W4303685481 cites W2092215629 @default.
- W4303685481 cites W2095861620 @default.
- W4303685481 cites W2101299592 @default.
- W4303685481 cites W2108410343 @default.
- W4303685481 cites W2116760308 @default.
- W4303685481 cites W2119043140 @default.
- W4303685481 cites W2120661754 @default.
- W4303685481 cites W2128402413 @default.
- W4303685481 cites W2128577473 @default.
- W4303685481 cites W2137228442 @default.
- W4303685481 cites W2137701916 @default.
- W4303685481 cites W2140948050 @default.
- W4303685481 cites W2143772132 @default.
- W4303685481 cites W2146292887 @default.
- W4303685481 cites W2146530991 @default.
- W4303685481 cites W2149748445 @default.
- W4303685481 cites W2150678612 @default.
- W4303685481 cites W2156383220 @default.
- W4303685481 cites W2157434805 @default.
- W4303685481 cites W2161426850 @default.
- W4303685481 cites W2166199281 @default.
- W4303685481 cites W2167733085 @default.
- W4303685481 cites W2218347603 @default.
- W4303685481 cites W2318605753 @default.
- W4303685481 cites W2337300757 @default.
- W4303685481 cites W2395845086 @default.
- W4303685481 cites W2460150844 @default.
- W4303685481 cites W2466446327 @default.
- W4303685481 cites W2507020595 @default.
- W4303685481 cites W2528228811 @default.
- W4303685481 cites W2557222435 @default.
- W4303685481 cites W2557666746 @default.
- W4303685481 cites W2560836545 @default.
- W4303685481 cites W2562493667 @default.
- W4303685481 cites W2565056077 @default.
- W4303685481 cites W2566747056 @default.
- W4303685481 cites W2567116115 @default.
- W4303685481 cites W2568031591 @default.
- W4303685481 cites W2571423414 @default.
- W4303685481 cites W2587931206 @default.
- W4303685481 cites W2593371437 @default.
- W4303685481 cites W2596133050 @default.
- W4303685481 cites W2610368132 @default.
- W4303685481 cites W2614773797 @default.
- W4303685481 cites W2622499649 @default.
- W4303685481 cites W2624590002 @default.
- W4303685481 cites W2738111927 @default.
- W4303685481 cites W2744067212 @default.
- W4303685481 cites W2752658156 @default.
- W4303685481 cites W2754075165 @default.
- W4303685481 cites W2755561465 @default.
- W4303685481 cites W2762577984 @default.
- W4303685481 cites W2766673799 @default.
- W4303685481 cites W2766889124 @default.
- W4303685481 cites W2767180992 @default.
- W4303685481 cites W2768649895 @default.
- W4303685481 cites W2770700940 @default.
- W4303685481 cites W2771541888 @default.
- W4303685481 cites W2781844803 @default.
- W4303685481 cites W2791139688 @default.
- W4303685481 cites W2791308824 @default.
- W4303685481 cites W2792583114 @default.